Neurotech's NTI164 Shows Promising Results in PANDAS/PANS Genomic Analysis
NTI (NTI) Share Update November 2024 Thursday 14th
Neurotech Confirms NTI164 Benefits in PANDAS/PANS Patients
Neurotech International Ltd (ASX: NTI) has announced promising results from a genomic analysis of PANDAS/PANS patients treated with their proprietary drug NTI164.
Instant Summary:
- Genomic analysis shows reversal of immune system dysregulation.
- NTI164 modulates immune system and protein translation at genomic and proteomic levels.
- Data confirms safety and effectiveness of NTI164 in inflammatory conditions.
- Additional patent application filed for NTI164.
Groundbreaking Genomic Analysis
Neurotech International Ltd has released the results of a genomic analysis conducted on patients with Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS). These patients participated in Neurotech's Phase I/II clinical trial, which showed significant improvements in symptoms such as anxiety and depression over 12, 24, and 52 weeks.
The genomic analysis, led by Professor Russell Dale's team, utilized advanced single-cell RNA sequencing to examine gene expression profiles in immune cells. Results indicated a reversal of immune system dysregulation in patients treated with NTI164, aligning with previously reported protein expression data.
Mechanism of Action
NTI164, a unique cannabinoid formulation, was shown to modulate immune response and protein translation at both genomic and proteomic levels. At baseline, PANDAS/PANS patients exhibited significant down-regulation in immune function pathways and up-regulation in protein translation pathways. After 12 weeks of NTI164 treatment, these gene signatures were largely normalized.
This normalization suggests that NTI164 not only has anti-inflammatory effects but also acts as an epigenetic modulator, potentially addressing the underlying causes of the neurological issues observed in PANDAS/PANS patients.
Future Prospects
The positive results reinforce the safety and efficacy of NTI164 under inflammatory conditions, with no activation of harmful cellular pathways. These findings have led Neurotech to file an additional patent application, highlighting the potential of NTI164 in treating neuropsychiatric disorders.
The company plans to submit the results to a leading scientific journal, further validating their research and potentially expanding the therapeutic applications of NTI164.
The confirmation of NTI164's benefits in normalizing immune gene expression could significantly enhance Neurotech's market position in the biopharmaceutical sector. This development may lead to increased investor interest and a potential rise in stock value as the drug progresses through further clinical trials.
Investor Reaction:
Analysts are likely to view this announcement positively, given the potential market for effective treatments for PANDAS/PANS. The additional patent application may also signal future growth opportunities for Neurotech.
Conclusion:
Investors should keep an eye on Neurotech's upcoming publications and patent developments. The promising results of NTI164 in treating PANDAS/PANS could pave the way for broader applications in other neurological disorders.